'On/Off' Science Careers Are Gaining Favor

There is a growing market out there for part-time and/or temporary work in the sciences. Employers have long seen the advantages—savings in overhead and benefits plus greater flexibility in many activities—but now the practice of research is changing, moving toward almost interchangeable scientists performing routine, clearly divided tasks. At the same time, based on our work in the professional relations office of the American Chemical Society I see an increasing interest in this

Written byTerrence Russell
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

At the same time, based on our work in the professional relations office of the American Chemical Society I see an increasing interest in this kind of arrangement among certain groups of scientists. We are moving toward an era of “modularity” of career stages: a preference for easy-in, easy-out, easy-return jobs.

Several forces are making part-time science feasible. As an example, the high-tech end of industrial chemistry is becoming more of a service industry. More chemists are not handling chemicals, but are creating information about highly engineered materials.

With this kind of activity work will be less tied to monitoring processes. And with automated laboratories, there will be even less demand for the chemist to be in a particular place at a particular time.

If we look at the economics, more market-driven research programs will mean less continuity of research effort and will make ad-hoc puzzle-solving teams more attractive. Employers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies